Clinical samples obtained from breast cancer patients who exhibited poor outcomes, including advanced stages, lymph node metastases, and decreased disease-free survival rates, underscore a direct relationship between increased vimentin and Slug expression and decreased miR-30a levels [12,13]. This evidence concerns the gene VIM and breast cancer.